🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
MRNA
NASDAQ
🇺🇸 US
Moderna, Inc.
Pharmaceuticals
22Score
DipBuster Score™
$140.33
$5.22 (0%)
Live price · Source: FMP-live
52-Week Position
$22.28
76% of range
$176.66
Beta
0.899
Market-like
Dividend
—
no income
Mkt Cap
$55.68B
total value
Mkt Cap$55.68B
P/EN/A
DividendNone
Beta0.899
52W High$176.66
52W Low$22.28
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Neutral
Mid-Range Position (76% of 52-Week Range)
The stock sits in the middle of its annual range — no extreme dip opportunity, but also not overextended.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt Cap$55.68B
52W Position76% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.899
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Moderna, Inc. (MRNA), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-08-28 | Hoge Stephen | SELL | 611 |
| 2026-08-28 | Hoge Stephen | SELL | 296 |
| 2026-08-28 | Hoge Stephen | BUY | 611 |
| 2026-08-28 | Klinger Shannon Thyme | SELL | 329 |
| 2026-08-28 | Klinger Shannon Thyme | SELL | 160 |
| 2026-08-28 | Klinger Shannon Thyme | BUY | 329 |
| 2026-08-28 | Mock James M | SELL | 329 |
| 2026-08-28 | Mock James M | SELL | 160 |
| 2026-08-28 | Mock James M | BUY | 329 |
| 2026-08-27 | Hoge Stephen | SELL | 1,437 |
Graham NCAV Analysis
Above net-net level
Current Assets$6.54B
Less: Total Liabilities−$3.69B
= Net Current Asset Value$2.86B
NCAV Per Share$7.2487
Current Price$145.55
Price / NCAV20.08×
Margin of Safety-1907.9%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market Cap$55.68B
Beta0.899
Dividend/yrNone
52W High$176.66
52W Low$22.28
52-Week Range
$22.28Now$176.66
76% through annual range
From 52W High−20.6%
From 52W Low+529.8%
📖 Plain English Summary
Moderna, Inc. is at 76% of its 52-week range. Beta 0.899 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for MRNA
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — MRNA
Heuristic · balance sheet, insider filings, price data, academic research
Moderna, Inc. — DipBuster Score 22/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Moderna, Inc. free
Add MRNA to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
9/25
Momentum & Volume
8/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
1
/100 · NEUTRAL
dip depth
1/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 22/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts targ…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Stéphane Bancel
Staff
4,700 employees
Website